SYK - CIK 0000310764
STRYKER CORP trades as SYK and has a market capitalization of $117.82 B, making it the #130 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $25.12B, up 11.2% from the prior year and net income of $3.25B. This page tracks STRYKER CORP through 1,000 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years STRYKER CORP's revenue grew from $11.32B to $25.12B, a compound annual growth rate of 9.3%. Net profit margin compressed from 14.5% to 12.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-20 |
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-11 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
| Insider trade | 4 | 2026-05-08 |
“This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease,” said Kevin Lobo, Chair and CEO, Stryker. “By integrating AVS’s innovative CO₂-generated pressure wave technology with Stryker’s scale and resources, we are well-positioned to deliver solutions that support physicians and patient outcomes.”
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.
Stryker to participate in the Bank of America Securities 2026 Global Healthcare Conference
The acquisition will strengthen Stryker’s Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker’s existing PV offerings and support the company’s strategy to expand its presence in arterial disease treatment.
The largest companies sharing STRYKER CORP's SEC industry classification (surgical & medical instruments & apparatus).
STRYKER CORP (SYK) has a market capitalization of $117.82 B as of 2026-06-10, ranking #130 among US-listed companies.
STRYKER CORP reported revenue of $25.12B for fiscal year 2025, an increase of 11.2% year over year.
Yes. STRYKER CORP reported net income of $3.25B in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.